Who
George Migausky V
Director
Company insider
Files Form 4 as: Director, Regenxbio; Director, Immunovant; Director, Abeona Therapeutics; Director, Dimension Therapeutics; EVP & Chief Financial Officer, Dyax; Chief Financial Officer, Bioveris.
In numbers
- Trades disclosed
- 135
- Buys
- 7
- Sells
- 7
- Bought
- $182K
- Sold
- $3.9M
- Companies
- 6
- Companies where not an officer
- 4
- First trade
- 15 Jun 2006
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —46,600 at $0.00 | filing |
| 29 May 2026filed 2 Jun 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —9,807 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —39,815 at $0.00 | filing |
| 30 May 2025filed 3 Jun 2025 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —7,768 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,600 at $0.00 | filing |
| 1 Apr 2025filed 3 Apr 2025 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code A | —16,188 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —24,454 at $0.00 | filing |
| 31 May 2024filed 4 Jun 2024 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —4,790 at $0.00 | filing |
| 2 Apr 2024filed 4 Apr 2024 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,690 at $0.00 | filing |
| 2 Apr 2024filed 4 Apr 2024 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code A | —11,255 at $0.00 | filing |
| 1 Dec 2023filed 5 Dec 2023 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $163K4,200 at $38.79 | filing |
| 1 Dec 2023filed 5 Dec 2023 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $138K3,478 at $39.81 | filing |
| 1 Dec 2023filed 5 Dec 2023 | IMVT ImmunovantBiotechnology | SEC FORM 4 Sold | $203K5,022 at $40.46 | filing |
| 2 Jun 2023filed 6 Jun 2023 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code A | —17,892 at $0.00 | filing |
| 2 Jun 2023filed 6 Jun 2023 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code A | —3,486 at $0.00 | filing |
| 12 Apr 2023filed 14 Apr 2023 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,260 at $0.00 | filing |
| 12 Apr 2023filed 14 Apr 2023 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code A | —12,523 at $0.00 | filing |
| 17 Aug 2022filed 19 Aug 2022 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,668 at $0.00 | filing |
News
Immunovant (NASDAQ:IMVT) Insider Tuyl Christopher Van Sells 1,327 Shares of Company StockIMVT · themarketsdaily.com · 10 Oct 2026Immunovant (NASDAQ:IMVT) Stock: Insider Jay Stout Sells 3,809 SharesIMVT · themarketsdaily.com · 9 Oct 2026Immunovant (NASDAQ:IMVT) CEO Sells $119,589.66 in StockIMVT · themarketsdaily.com · 8 Oct 2026
0 headlines in the last 90 days name George Migausky V; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.